FARMINGDALE, N.Y., Sept. 3 Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced its attendance at the XIV World Congress of Neurological Surgery, August 30 - September 4, 2009 in Boston, Massachusetts. The World Congress, which is held every 4 years, is sponsored by the World Federation of Neurosurgical Societies ("WFNS"). Approximately 3,000 neurosurgeons from around the world were in attendance.
Founded in 1955, the WFNS is a professional, scientific, non-governmental organization comprised of 5 Continental Associations, 98 National Neurosurgical Societies and 6 Affiliate Societies, representing some 30,000 neurosurgeons worldwide. Key components of their mission are to exchange and disseminate knowledge and encourage research while implementing, improving and promoting standards of neurosurgical care.
The Company exhibited and demonstrated its SonaStar(R) Ultrasonic Surgical Aspiration System and its BoneScalpel(TM) Ultrasonic Bone Cutting System to the attending delegates. In addition, the Company's product presentations were filmed by WFNS representatives and will be featured on their website for approximately 1 year. Company presentations will be added to the site on or about October 1, 2009 and will be accessible at www.wfns.org/virtualexhibithall.
The SonaStar is used by Neurosurgeons and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, the Company's OsteoSculpt(TM) bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.
The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.
"Misonix is pleased to demonstrate its commitment to the neurosurgery community by supporting important educational programs like WFNS," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We believe our SonaStar and BoneScalpel product platforms can make important contributions to improving neurosurgical patient outcomes."
Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward-looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Investor Relations Contact: Cameron Associates, Inc. Kevin McGrath 212-245-4577 [email protected]
SOURCE Misonix, Inc.